SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Beyond Air, Inc. (XAIR) (CIK 0001641631) (XAIR) — May 7, 2020

Beyond Air, Inc. (XAIR) (CIK 0001641631)
Date: May 7, 2020 · CIK: 0001641631 · Accession: 0000000000-20-003985

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-237958

Date
May 6, 2020
Author
Steven Lisi
Form
UPLOAD
Company
Beyond Air, Inc. (XAIR) (CIK 0001641631)

Letter

United States securities and exchange commission logo May 6, 2020 Steven Lisi Chairman and Chief Executive Officer Beyond Air, Inc. 825 East Gate Blvd., Suite 320 Garden City, NY 11530 Re:Beyond Air, Inc. Registration Statement on Form S-3 Filed May 1, 2020 File No. 333-237958 Dear Mr. Lisi: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Avital Perlman, Esq.

Show Raw Text
United States securities and exchange commission logo
May 6, 2020
Steven Lisi
Chairman and Chief Executive Officer
Beyond Air, Inc.
825 East Gate Blvd., Suite 320
Garden City, NY 11530
Re:Beyond Air, Inc.
Registration Statement on Form S-3
Filed May 1, 2020
File No. 333-237958
Dear Mr. Lisi:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Avital Perlman, Esq.